Bluefin Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bluefin Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-52,600	Closed	-$263	–	160
2023 Q4	$263	Buy	+52,600	New	+$2.76M	﹤0.01%	245
2022 Q2	–	Sell	-200,100	Closed	-$890K	–	606
2022 Q1	$890K	Buy	+200,100	New	+$13.4M	0.08%	142
2020 Q4	–	Hold	0	–	-$30K	–	695
2020 Q3	–	Sell	-37,400	Closed	-$2.25M	–	393
2020 Q2	$92K	Sell	37,400 -104,000	-74%	-$6.22M	0.01%	276
2020 Q1	$124K	Buy	141,400 +2,800	+2%	+$171K	0.02%	280
2019 Q4	$274K	Sell	138,600 -88,000	-39%	-$5.04M	0.02%	355
2019 Q3	$549K	Sell	226,600 -14,900	-6%	-$700K	0.08%	168
2019 Q2	$254K	Sell	241,500 -2,258,000	-90%	-$105M	0.04%	204
2019 Q1	$1.29M	Buy	+2,499,500	New	+$125M	0.19%	83

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bluefin Capital Management's BMY Position: Q2 2026 in Review

Bluefin Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 62% in Q2 2026, selling an estimated $365K and leaving 3,950 shares worth $228K. The position accounts for 0.06% of the portfolio, ranked #87.

Bluefin Capital Management first reported a position in BMY in Q2 2013 and has held it in 32 quarters since. The position peaked at $18.3M in Q4 2019. 2,526 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Bluefin Capital Management held 3,950 shares of Bristol-Myers Squibb worth $228K as of Q2 2026.
Bluefin Capital Management sold 6,350 Bristol-Myers Squibb shares in Q2 2026, an estimated $365K.
Bristol-Myers Squibb made up 0.06% of Bluefin Capital Management's portfolio in Q2 2026, its #87 holding.
Bluefin Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 32 quarters since.
Bluefin Capital Management's Bristol-Myers Squibb position peaked at $18.3M in Q4 2019.
2,526 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Bluefin Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.